$ELVN News

Enliven Therapeutics To Present Updated Phase 1 ELVN-001 Data In Chronic Myeloid Leukemia At EHA 2026 And Host Investor Webcast On June 11 At 8:30 a.m. ET

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Enliven Therapeutics To Present Phase 1 CML Data For ELVN-001, Showing Durable Molecular Response Rates And Favorable Safety In Heavily Pretreated Patients At EHA 2026

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $59

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Enliven Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating and raised the price target on the stock from $48 to $56.

Enliven Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating and raised the price target on the stock from $48 to $56.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $56

Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’

Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $45

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Enliven Therapeutics: Q4 Earnings Insights

Enliven Therapeutics Q4 EPS $(0.48) Misses $(0.38) Estimate

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious

Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data